Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History by Andrew Blauvelt, Howard Kallender, Daniel Sturm, Qian Li, Haobo Ren, Lawrence F. Eichenfield

Get full text

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies by Eric L. Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F. Eichenfield

Get full text

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adoles... by Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, Howard Kallender, Daniel Sturm, Haobo Ren, Linda F. Stein Gold

Get full text

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours by Michael Smith, Aung Naing, Todd Bauer, Kyriakos P Papadopoulos, Osama Rahma, Elena Garralda, Glenn J Hanna, Michael J Pishvaian, Xuejun Chen, Sven Gogov, Omar Saavedra, Howard Kallender, LuLu Cheng, Emil Kuriakose

Get full text

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. by Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P Bottaro

Get full text